1
|
Torralba M, Rodríguez G, González Gasca FJ, Cuadra F, Barberá J, Geijo P, Silva A, García MI, Ostaiza MA, García Pérez AM, Arroyo E, Larrubia JR, Gutiérrez A, Porras ML, Calvo Sánchez H, Peña-Asensio J, Arias JG, Mendoza I. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain. Ann Pharmacother 2024; 58:140-147. [PMID: 37131300 DOI: 10.1177/10600280231168852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023] Open
Abstract
BACKGROUND The evaluation of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in clinical trials has shown high rates of virological suppression but information about its use in real-life settings is scarce. OBJECTIVE To evaluate the effectiveness, safety, durability, and predictive variables of therapeutic failure of BIC/FTC/TAF in a real-life cohort. METHODS This observational, retrospective, multicentered cohort study included treatment-naive (TN) and treatment-experienced (TE) adult patients living with HIV (PLWH) who started treatment with BIC/FTC/TAF from January 1, 2019, to January 31, 2022. Treatment effectiveness (based on intention-to-treat [ITT], modified ITT [mITT], and on-treatment [OT]), tolerability, and safety were evaluated in all patients who started BIC/FTC/TAF antiretroviral therapy. RESULTS We included a total of 505 PLWH of whom 79 (16.6%) were TN and 426 (83.4%) were TE. Patients were followed up for a median (interquartile range [IQR]) of 19.6 (9.6-27.3) months, and 76% and 56% of PLWH reached month 6 and month 12 of treatment, respectively. Rates of TN PLWH with HIV-RNA <50 copies/mL in the OT, mITT, and ITT groups were 94%, 80%, and 62%, respectively, after 12 months of BIC/FTC/TAF treatment. Rates of TE PLWH with HIV-RNA <50 copies/mL were 91%, 88%, and 75% at month 12. The multivariate analysis revealed that neither age, sex, CD4 cell count <200 cells/μL, or viral load >100 000 copies/mL were associated with therapeutic failure. CONCLUSION AND RELEVANCE Our real-life data showed that BIC/FTC/TAF is effective and safe for use in the treatment of both TN and TE patients in clinical practice.
Collapse
Affiliation(s)
- Miguel Torralba
- Servicio de Medicina Interna, Hospital Universitario de Guadalajara, Guadalajara, Spain
- Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Madrid, Spain
| | - Gema Rodríguez
- Servicio de Medicina Interna, Hospital General Universitario de Albacete, Albacete, Spain
| | | | - Fernando Cuadra
- Servicio de Medicina Interna, Hospital Universitario de Toledo, Toledo, Spain
| | - José Barberá
- Servicio de Medicina Interna, Hospital General La Mancha-Centro, Ciudad Real, Spain
| | - Paloma Geijo
- Servicio de Medicina Interna, Hospital General Virgen de la Luz, Cuenca, Spain
| | - Andrea Silva
- Servicio de Medicina Interna, Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain
| | | | | | - Ana María García Pérez
- Servicio de Medicina Interna, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - Esther Arroyo
- Servicio de Medicina Interna, Hospital General La Mancha-Centro, Ciudad Real, Spain
| | - Juan Ramón Larrubia
- Servicio de Gastroenterología, Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - Almudena Gutiérrez
- Servicio de Medicina Interna, Hospital General Universitario de Albacete, Albacete, Spain
| | - María Lourdes Porras
- Servicio de Medicina Interna, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - Henar Calvo Sánchez
- Servicio de Gastroenterología, Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - Julia Peña-Asensio
- Departamento de Biología de Sistemas, Universidad de Alcalá, Alcala de Henares, Spain
| | - Julio Gabriel Arias
- Servicio de Medicina Interna, Hospital General Universitario de Albacete, Albacete, Spain
| | - Inés Mendoza
- Servicio de Farmacia Hospitalaria, Hospital Universitario de Guadalajara, Guadalajara, Spain
| |
Collapse
|